And so, look, I feel as good as you can feel with the position that we have. But again, we win patient-by-patient, we win market-by-market, we win hospital-by-hospital or prescriber-by-prescriber. And so, we don’t take anything for granted on that, and we’re going to continue to pursue what we think is above market growth, given the opportunities that we have and given the focus of our team in developing the relationships and providing real solutions to our key stakeholders.
Lisa Gill: Great. Thank you so much.
John Rademacher: Yeah. Thanks, Lisa.
Operator: Thank you. Our next question comes from the line of Pito Chickering with Deutsche Bank. Your line is open.
Pito Chickering: Hey. Good morning, guys. Thanks for taking the questions. Back to Lisa’s revenue growth questions again. If you exclude respiratory therapy, what revenues have been growing for 2023?
Michael Shapiro: Yeah. So we don’t — we haven’t broken it out in great detail. It’s in the neighborhood of $20 million to $25 million of top line for that therapy line. It’s relatively limited.
Pito Chickering: Okay. Fair enough. And then maybe I missed it, but to the question about what do you guys assuming for chronic growth for 2023 and acute growth for 2023 net of the ASP pressure? Is that — did you put actual numbers on that within better than guidance?
Michael Shapiro: Yes. No, we don’t break out specific guidance for the categories. Again, the way we have broadly characterized it Pito, is that obviously, the acute portfolio is a slower growing, more mature portfolio of therapies and the chronic is typically in that low double-digit category. Again, there is a couple of disruptions from some therapies that are being disrupted with other therapies. But I would say those general growth descriptors remain intact for ’23.
Pito Chickering: Okay. Perfect. And then for the ASP pressure in the 100 basis points, what’s the EBITDA impact of that? Does that flow straight through, or is a lot of that variable? And what percent of your portfolio are those antibiotics? Is that the bulk of your acute portfolio?
Michael Shapiro: No. Look, intravenous antibiotics is a key therapy for us, it’s one of our larger therapy categories, but it’s not the majority of our acute revenue. And look, obviously, a lot of our revenue is comprised of billing for the therapeutic, which is an ASP or an AWP reference. That also has a correlation to our procurement. So as ASPs increase or decrease, there is a general correlation to our procurement costs. So I wouldn’t necessarily assume that, that point of revenue drops dollar for dollar. Obviously, we make a margin on a drug revenue x percent of a smaller number is a smaller number, but there is some muting of the revenue impact through our procurement strategy.
Pito Chickering: Okay. Great. And then last question, the target for one to three new limited drug distributions also the ones that age out. Is there any change in the ability to get sort of to land those deals? Is it becoming more competitive or is this more of a timing issue?
